Key Highlights
- Aleniglipron, Structure Therapeutics’ oral GLP-1 candidate, achieved 16.3% placebo-adjusted weight reduction at week 44 in the Phase 2 ACCESS II study
- The drug’s performance exceeded oral GLP-1 competitors from Novo Nordisk (13.6%) and Eli Lilly (12.4%) in comparable Phase 2 trials
- Data revealed continued weight reduction with no plateau effect, distinguishing it from rival therapies
- GPCR shares climbed approximately 10% on Monday, reaching $59.80 following the announcement
- The company plans an FDA end-of-Phase 2 consultation in Q2 2026, with Phase 3 trials scheduled for H2 2026
Structure Therapeutics unveiled impressive Phase 2 results for aleniglipron, its oral GLP-1 obesity treatment, on Monday, propelling GPCR shares upward by roughly 10% during morning market hours.
Structure Therapeutics Inc., GPCR
The ACCESS II study demonstrated placebo-adjusted weight reduction of 16.3% with the 180 mg dosage and 16.0% with the 240 mg dosage at 44 weeks. Notably, both dosage levels exhibited ongoing weight loss without reaching a plateau.
These figures compare favorably against competitive offerings. Novo Nordisk’s oral Wegovy formulation achieved 13.6% weight reduction in Phase 3 studies. Eli Lilly’s orforglipron delivered approximately 12.4% in Phase 2 trials, declining to 11.2% in Phase 3 testing.
Previous data released in December had demonstrated 14.2% weight reduction at a reduced dose. Participants who remained on that lower dosage for 53 weeks ultimately achieved 16% weight loss, suggesting sustained therapeutic benefits over extended periods.
Safety and tolerability metrics remained favorable. The ACCESS Open Label Extension trial reported only a 2% discontinuation rate due to adverse events. The body composition analysis indicated a 3.4% rate. Structure’s strategy of initiating treatment at a low 2.5 mg dose appears to enhance patient compliance and treatment persistence.
The positive outcomes have sparked acquisition speculation. H.C. Wainwright analyst Ananda Ghosh previously identified aleniglipron this month as “the most acquirable asset in obesity.” The firm elevated its price target to $114. Citizens maintained a Market Outperform rating while adjusting its target to $113.
Analyst Reactions
Leerink Partners reaffirmed its Outperform rating and $90 price objective following the data release. The firm emphasized the favorable tolerability profile and clear dose-response correlation as significant advantages.
RBC Capital Markets adopted a more cautious stance. Analyst Trung Huynh observed that orforglipron showed comparable Phase 2 performance before declining in Phase 3. He identified an atypically low placebo group weight gain as a statistical anomaly warranting attention. RBC maintained its Outperform rating on Lilly with a $1,250 price objective.
“It’s difficult to characterize these results as meaningfully differentiated from Orfo or oral Wegovy until we get a more robust data set,” Huynh wrote.
What Comes Next
Structure Therapeutics has scheduled an end-of-Phase 2 consultation with the FDA during Q2 2026. Phase 3 trials are anticipated to commence in the latter half of 2026. The company will leverage Phase 2 data from both elevated dosages to determine which proceeds to late-stage development.
Despite Monday’s gains, the stock remains down 23% year-to-date, though it has surged 155% over the trailing twelve months. At $59.80, shares trade substantially below analyst consensus projections, which span from $90 to $140.
Cantor Fitzgerald had previously identified this 44-week data readout as a significant catalyst for the stock. That projection materialized accurately.
Monday’s rally elevated GPCR’s market capitalization to approximately $3.81 billion.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
